Could hyaluronic acid (HA) reduce Bacillus Calmette-Guérin (BCG) local side effects? Results of a pilot study

Luca Topazio, Roberto Miano, Valentina Maurelli, Gabriele Gaziev, Mauro Gacci, Valerio Iacovelli, Enrico Finazzi-Agrò, Luca Topazio, Roberto Miano, Valentina Maurelli, Gabriele Gaziev, Mauro Gacci, Valerio Iacovelli, Enrico Finazzi-Agrò

Abstract

Background: Bacillus Calmette-Guérin (BCG) is considered the most effective treatment to reduce recurrence and progression of non-muscle invasive bladder cancer (NMIBC) but can induce local side effects leading to treatment discontinuation or interruption. Aim of this exploratory study is to investigate if the sequential administration of Hyaluronic acid (HA) may reduce local side effects of BCG.

Methods: 30 consecutive subjects undergoing BCG intravesical administration for high risk NMIBC were randomized to receive BCG only (Group A) or BCG and HA (Group B). A 1 to 10 Visual Analog Scale (VAS) for bladder pain, International Prostate Symptom Score (IPSS) and number of micturitions per day were evaluated in the two groups before and after six weekly BCG instillations. Patients were also evaluated at 3 and 6 months by means of cystostopy and urine cytology.

Results: One out of 30 (3,3%) patients in group A dropped out from the protocol, for local side effects. Mean VAS for pain was significantly lower in group B after BCG treatment (4.2 vs. 5.8, p = 0.04). Post vs. pre treatment differences in VAS for pain, IPSS and number of daily micturitions were all significantly lower in group B. Three patients in group A and 4 in group B presented with recurrent pathology at 6 month follow up.

Conclusions: These preliminary data suggest a possible role of HA in reducing BCG local side effects and could be used to design larger randomized controlled trials, assessing safety and efficacy of sequential BCG and HA administration.

Trial registration: NCT02207608 (ClinicalTrials.gov) 01/08/2014. Policlinico Tor Vergata Ethics Committee, resolution n 69-2011.

References

    1. Gontero P, Bohle A, Malmstrom PU, O’Donnell MA, Oderda M, Sylvester R, Witjes F. The role of bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer. Eur Urol. 2010;57(3):410–429. doi:10.1016/j.eururo.2009.11.023. Epub 2009 Nov 13.
    1. Lamm DL, van der Meijden PM, Morales A, Brosman SA, Catalona WJ, Herr HW, Soloway MS, Steg A, Debruyne FM. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol. 1992;147(3):596–600.
    1. Drake MJ, Nixon PM, Crew JP. Drug-induced bladder and urinary disorders. Incidence, prevention and management. Drug Saf. 1998;19(1):45–55.
    1. Witjes JA, Palou J, Soloway M, Lamm D, Brausi M, Spermon JR, Persad R, Buckley R, Akaza H, Colombel M, Böhle A. Clinical practice recommendations for the prevention and management of intravesical therapy-associated adverse events. Eur Urol Suppl. 2008;7(10):667–674.
    1. Vegt PD, van der Meijden AP, Sylvester R, Brausi M, Höltl W, de Balincourt C. Does isoniazid reduce side effects of intravesical bacillus Calmette-Guerin therapy in superficial bladder cancer? Interim results of European Organization for Research and Treatment of Cancer Protocol 30911. J Urol. 1997;157(4):1246–1249.
    1. Colombel M, Saint F, Chopin D, Malavaud B, Nicolas L, Rischmann P. The effect of ofloxacin on bacillus Calmette-Guérin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double blind, placebo controlled, multicenter study. J Urol. 2006;176:935.
    1. O’Donnell M. Does ofloxacin protect against BCG related toxic effects in patients with bladder cancer? Nat Clin Pract Urol. 2007;4:304.
    1. Martínez-Piñeiro JA, Flores N, Isorna S, Solsona E, Sebastián JL, Pertusa C, Rioja LA, Martínez-Piñeiro L, Vela R, Camacho JE, Nogueira JL, Pereira I, Resel L, Muntañola P, Galvis F, Chesa N, De Torres JA, Carballido J, Bernuy C, Arribas S, Madero R. for CUETO (Club Urológico Español de Tratamiento Oncológico) Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int. 2002;89(7):671–680.
    1. Iacovelli V, Topazio L, Gaziev G, Bove P, Vespasiani G, Finazzi Agrò E. Intravesical glycosaminoglycans in the management of chronic cystitis. Minerva Urol Nefrol. 2013;65(4):249–262.
    1. Madersbacher H, van Ophoven A, van Kerrebroeck PE. GAG layer replenishment therapy for chronic forms of cystitis with intravesical glycosaminoglycans–a review. Neurourol Urodyn. 2013;32(1):9–18. doi:10.1002/nau.22256. Epub 2012 Jul 10.
    1. Sommariva ML, Sandri SD, Guerrer CS. Treatment of acute iatrogenic cystitis secondary to bladder chemo-immuno-instillation or pelvic radiotherapy. Urologia. 2010;77:187.
    1. Fowler S, Daukeh M, Thompson A. Intravesical sodium hyaluronate (Cystistat®) as a treatment for chronic BCG Cystitis: a discussion of two successful cases. [ ]
    1. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466–4755. discussion 475–7. Epub 2006 Jan 17.
    1. Shelley MD, Kynaston H, Court J, Wilt TJ, Coles B, Burgon K, Mason MD. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int. 2001;88(3):209–216.
    1. Han RF, Pan JG. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology. 2006;67(6):1216.
    1. Böhle A, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumour progression. Urology. 2004;63(4):682.
    1. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168(5):1964.
    1. Van der Meijden APM, Sylvester RJ, Oosterlinck W, Hoeltl W, Bono AV. EORTC Genito-Urinary Tract Cancer Group. Maintenance bacillus Calmette-Guerin for TaT1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group phase III trial. Eur Urol. 2003;44:429.
    1. Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163(4):1124–1129.
    1. Saint F, Irani J, Patard JJ, Salomon L, Hoznek A, Zammattio S, Debois H, Abbou CC, Chopin DK. Tolerability of bacille Calmette-Guérin maintenance therapy for superficial bladder cancer. Urology. 2001;57(5):883–888.
    1. Martínez-Piñeiro JA, Martínez-Piñeiro L, Solsona E, Rodríguez RH, Gómez JM, Martín MG, Molina JR, Collado AG, Flores N, Isorna S, Pertusa C, Rabadán M, Astobieta A, Camacho JE, Arribas S, Madero R. Club Urológico Español de Tratamiento Oncológico (CUETO) Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol. 2005;174(4 Pt 1):1242–1247.
    1. Oddens J, Brausi M, Sylvester R, Bono A, van de Beek C, van Andel G, Gontero P, Hoeltl W, Turkeri L, Marreaud S, Collette S, Oosterlinck W. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol. 2013;63(3):462–472. doi: 10.1016/j.eururo.2012.10.039. Epub 2012 Nov 2.
    1. Toft BR, Nordling J. Recent developments of intravesical therapy of painful bladder syndrome/interstitial cystitis: a review. Curr Opin Urol. 2006;16:268.
    1. Nickel JC, Egerdie B, Downey J, Singh R, Skehan A, Carr L, Irvine-Bird K. A real-life multicentre clinical practice study to evaluate the efficacy and safety of intravesical chondroitin sulphate for the treatment of interstitial cystitis. BJU Int. 2009;103(1):56–60. doi:10.1111/j.1464-410X.2008.08028.x. Epub 2008 Sep 3.
    1. Hurst RE. Structure, function, and pathology of proteoglycans and glycosaminoglycans in the urinary tract. World J Urol. 1994;12:3.
    1. Leppilahti M, Hellström P, Tammela TLJ. Effect of diagnostic hydrodistension and four intravesical Hyaluronan Instillations on bladder ICAM-1 intensity and association of ICAM-1 intensity with clinical response in patients with interstitial cystitis. Urology. 2002;60:46.
    1. Schulz A, Vestweber AM, Dressler D. Anti-inflammatory action of a hyaluronic acid-chondroitin sulphate preparation in an in vitro bladder model. Akt Urol. 2009;40(2):109.
    1. Boucher WS, Letourneau R, Huang M, Kempuraj D, Green M, Sant GR, Theoharides TC. Intravesical sodium hyaluronate inhibits the rat urinary mast cell mediator increase triggered by acute immobilization stress. J Urol. 2002;167(1):380–384.
    1. Sylvester RJ, van der Meijden APM, Oosterlinck W, Hoeltl W, Bono AV. EORTC Genito-Urinary Tract Cancer Group. The side effects of bacillus Calmette-Guérin in the treatment of TaT1 bladder cancer do not predict its efficacy: results from a European Organization for Research and Treatment of Cancer Genito-Urinary Group phase III trial. Eur Urol. 2003;44:423.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner